8-K: Harvard Bioscience Reports Fourth Quarter and Full-Year 2024 Financial Results Amidst Challenging Market

Harvard Bioscience announces its Q4 and full-year 2024 financial results, showing a revenue decrease but improved net income in Q4, while navigating a difficult market environment.

Summary

• Harvard Bioscience reported revenues of $24.6 million for the fourth quarter of 2024, compared to $28.2 million in the fourth quarter of 2023.
• The gross margin for Q4 2024 was 57.1%, a slight decrease from 58.0% in 2023.
• Net income for the fourth quarter of 2024 was $18 thousand, a significant improvement compared to a loss of $(1.8) million in the fourth quarter of 2023.
• Adjusted EBITDA for the fourth quarter of 2024 was $3.0 million, down from $3.6 million in the prior year.
• For the full year 2024, revenues were $94.1 million, compared to $112.3 million in 2023.
• The gross margin for the year ended December 31, 2024, was 58.2%, compared to 58.9% in the prior year.
• Net loss for the year ended December 31, 2024, was ($12.4) million, compared to a net loss of $(3.4) million for the year ended 2023.
• Adjusted EBITDA for the year ended December 31, 2024, was $7.2 million, compared to $14.6 million for the year ended 2023.
• The company expects Q1 2025 revenues to be between $19 million and $21 million, with a gross margin in the 56% to 58% range.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company highlights positive market reception of new products and improved net income in Q4, the overall financial results show a decline in revenue and profitability for the full year, and the company is facing market uncertainties.

Positives

• Net income for the fourth quarter of 2024 improved significantly to $18 thousand compared to a loss of $(1.8) million in the fourth quarter of 2023.
• The company is seeing strong interest in new products like SoHo telemetry systems and MeshMEA organoid systems.
• Cost containment actions helped to partially offset the impact of lower revenues on the full-year net loss.

Negatives

• Fourth quarter revenues decreased to $24.6 million from $28.2 million in the same period last year.
• Full-year revenues decreased to $94.1 million from $112.3 million in the previous year.
• The company experienced a net loss of ($12.4) million for the full year, compared to a net loss of ($3.4) million in the prior year.
• Adjusted EBITDA decreased for both the fourth quarter and the full year.
• Cash provided by operations decreased significantly for both the three months and year ended December 31, 2024.

Risks

• The company faces uncertainty in NIH funding and academic research purchasing.
• The company is navigating a challenging global market environment.
• Reduced spending by CROs, distributors, and academic research institutions impacted revenues.
• The company's ability to continue as a going concern, fund operations, or refinance outstanding indebtedness is a risk.

Future Outlook

The company expects Q1 2025 revenues of $19 million to $21 million and gross margin in the 56% to 58% range, given the uncertainty in NIH funding and academic research purchasing, along with normal seasonality.

Management Comments

• Jim Green, Chairman and CEO, noted sequential strengthening in pre-clinical revenues across all regions in Q4.
• Jim Green mentioned that CMT revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers.
• Jim Green stated the company is encouraged by the strong market reception of new products.
• Jim Green emphasized the company's focus on managing costs to improve operating and financial performance.

Industry Context

The announcement reflects the challenges faced by life science companies due to market uncertainty and reduced spending by key customer segments like CROs and academic institutions. The company's focus on new product development and cost management aligns with strategies employed by other companies in the sector to navigate these challenges.

Comparison to Industry Standards

• Given the lack of specific comparible companies, projects, and results in the document, a detailed comparison to industry standards is not possible.
• However, the decline in revenue and adjusted EBITDA suggests that Harvard Bioscience is underperforming compared to industry leaders who have managed to maintain growth despite market headwinds.
• Companies like Thermo Fisher Scientific and Danaher have shown more resilience through diversification and strategic acquisitions.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and profitability.
• Employees may be affected by cost containment actions.
• Customers may benefit from new product offerings.
• Suppliers may experience reduced orders due to lower revenues.

Key Dates